TrialBlood2010

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Fabio P S Santos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.